The objective of this randomised, double blind, placebo controlled trial was to determine if inhaled and intranasal ciclesonide are superior to placebo at decreasing respiratory symptoms in adult outpatients with COVID-19.
In this trial, done at 43 centres in France, the authors randomly assigned patients receiving invasive mechanical ventilation for up to 72 h with COVID-19 and associated moderate-to-severe ARDS to receive either IVIG or placebo.
In this trial, nonhospitalized patients with symptomatic COVID-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression received a single infusion of sotrovimab at a dose of 500 mg or placebo.
Evaluation of the effects of therapeutic-dose low-molecular-weight heparin vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.
The objective of this study was to assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable outpatients with COVID-19.
The objective of this study was to investigate the seroprevalence and the quantity of SARS-CoV-2 antibodies in a cohort of patients with MS or NMO-SD. Blood samples were collected in patients diagnosed with COVID-19.
The authors of this article hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity.
In this study the authors aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community.
This study randomly assigned participants who were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection to receive a total dose of 1200mg of REGEN-COV or matching placebo administered by means of subcutaneous injection.
In this open-label, adaptive, multiplatform, randomized clinical trial, critically ill COVID-19 patients were randomly assigned to a regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care.